<VariationArchive VariationID="3244557" VariationName="NC_000011.9:g.(?_64550219)_(64573119_?)del" VariationType="Deletion" Accession="VCV003244557" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-07" DateCreated="2024-06-30" MostRecentSubmission="2024-06-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3403481" VariationID="3244557">
      <GeneList>
        <Gene Symbol="MAP4K2" FullName="mitogen-activated protein kinase kinase kinase kinase 2" GeneID="5871" HGNC_ID="HGNC:6864" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="64784918" stop="64803214" display_start="64784918" display_stop="64803214" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="64556608" stop="64570712" display_start="64556608" display_stop="64570712" Strand="-" />
          </Location>
          <OMIM>603166</OMIM>
        </Gene>
        <Gene Symbol="MEN1" FullName="menin 1" GeneID="4221" HGNC_ID="HGNC:7010" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="64803516" stop="64811294" display_start="64803516" display_stop="64811294" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="64570985" stop="64578765" display_start="64570985" display_stop="64578765" Strand="-" />
          </Location>
          <OMIM>613733</OMIM>
          <Haploinsufficiency last_evaluated="2022-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MEN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MEN1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000011.9:g.(?_64550219)_(64573119_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" innerStart="64550219" innerStop="64573119" display_start="64550219" display_stop="64573119" variantLength="22901" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.(?_64550219)_(64573119_?)del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.(?_64550219)_(64573119_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000011.9:g.(?_64550219)_(64573119_?)del AND Multiple endocrine neoplasia, type 1" Accession="RCV004580144" Version="1">
        <ClassifiedConditionList TraitSetID="5472">
          <ClassifiedCondition DB="MedGen" ID="C0025267">Multiple endocrine neoplasia, type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-03-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-03-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-06-30" MostRecentSubmission="2024-06-29">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10090472</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15331604</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16449969</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5472" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="12656" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MEN I</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Endocrine adenomatosis multiple</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEN 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Wermer syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Multiple endocrine neoplasia, type 1</ElementValue>
                <XRef ID="Multiple+endocrine+neoplasia+type+1/4955" DB="Genetic Alliance" />
                <XRef ID="30664006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEA I</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MEN1</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Multiple endocrine neoplasia type 1 (MEN1) includes varying combinations of more than 20 endocrine and non-endocrine tumors. Endocrine tumors become evident either by overproduction of hormones by the tumor or by growth of the tumor itself. Parathyroid tumors are the most common MEN1-associated endocrinopathy; onset in 90% of individuals is between ages 20 and 25 years with hypercalcemia evident by age 50 years; hypercalcemia causes lethargy, depression, confusion, anorexia, constipation, nausea, vomiting, diuresis, dehydration, hypercalciuria, kidney stones, increased bone resorption/fracture risk, hypertension, and shortened QT interval. Pituitary tumors include prolactinoma (the most common), which manifests as oligomenorrhea/amenorrhea and galactorrhea in females and sexual dysfunction in males. Well-differentiated endocrine tumors of the gastro-entero-pancreatic (GEP) tract can manifest as Zollinger-Ellison syndrome (gastrinoma); hypoglycemia (insulinoma); hyperglycemia, anorexia, glossitis, anemia, diarrhea, venous thrombosis, and skin rash (glucagonoma); and watery diarrhea, hypokalemia, and achlorhydria syndrome (vasoactive intestinal peptide [VIP]-secreting tumor). Carcinoid tumors are non-hormone-secreting and can manifest as a large mass after age 50 years. Adrenocortical tumors can be associated with primary hypercortisolism or hyperaldosteronism. Non-endocrine tumors include facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas, and leiomyomas.</Attribute>
                <XRef ID="NBK1538" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3829" />
                <XRef ID="3829" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301710</ID>
                <ID Source="BookShelf">NBK1538</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="Brandi et al., 2001">
                <ID Source="PubMed">11739416</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="Thakker et al., 2012">
                <ID Source="PubMed">22723327</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="652" DB="Orphanet" />
              <XRef ID="C0025267" DB="MedGen" />
              <XRef ID="D018761" DB="MeSH" />
              <XRef ID="MONDO:0007540" DB="MONDO" />
              <XRef Type="MIM" ID="131100" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="9835070" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-29" DateCreated="2024-06-29">
        <ClinVarSubmissionID localKey="NC_000011.9:g.(?_64550219)_(64573119_?)del|MedGen:C0025267" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005062653" DateUpdated="2024-06-29" DateCreated="2024-06-29" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15331604</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16449969</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10090472</ID>
          </Citation>
          <Comment>This frameshift change truncates the functionally conserved NLS2 domain of the MEN1 protein. Experimental studies have shown that disruption of this region abrogates the ability of MEN1 to bind DNA, regulate target gene expression, and inhibit cell proliferation (PMID: 15331604, 16449969). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the MEN1 protein. Other variant(s) that disrupt this region (p.Lys559Glufs*38) have been determined to be pathogenic (PMID: PMID: 10090472, Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has been observed in individual(s) with clinical features of multiple endocrine neoplasia type 1 (Invitae). This variant results in the deletion of exon(s) 9-10 and part of exon 8 (c.1173_*21587del) of the MEN1 gene. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Read depth</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.(?_64550219)_(64573119_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0025267" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14505471</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9835070" TraitType="Disease" MappingType="XRef" MappingValue="C0025267" MappingRef="MedGen">
        <MedGen CUI="C0025267" Name="Multiple endocrine neoplasia, type 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

